| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
47.61(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,511 |
191,640 |
263,030 |
1,586,782 |
| Total Sell Value |
$37,495 |
$144,338 |
$351,679 |
$10,312,191 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
38 |
59 |
108 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brainard Diana |
Chief Executive Officer |
• • – |
2023-07-19 |
4 |
S |
$3.56 |
$29,710 |
D/D |
(8,342) |
907,299 |
|
54% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-07-05 |
4 |
S |
$3.05 |
$9,084 |
D/D |
(2,983) |
1,186,852 |
|
56% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-07-05 |
4 |
S |
$3.05 |
$16,063 |
D/D |
(5,275) |
915,641 |
|
56% |
|
| Piccina Cintia |
Chief Commercial Officer |
• – – |
2023-07-03 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
147,000 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2023-06-27 |
4 |
B |
$3.75 |
$10,990,763 |
D/D |
2,930,870 |
16,635,286 |
2.45 |
-45% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-06-09 |
4 |
AS |
$5.64 |
$28,453 |
D/D |
(5,045) |
129,512 |
|
-70% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-05-18 |
4 |
S |
$4.21 |
$19,115 |
D/D |
(4,536) |
916,628 |
|
46% |
|
| Brenner Malcolm |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
65,197 |
|
- |
|
| Jovan-Embiricos Morana |
Director |
– • • |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
65,197 |
|
- |
|
| Adams Derek N. |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Bornstein Jeffrey S |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
75,197 |
|
- |
|
| Tomasello Shawn |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Hallal David |
Director |
– • • |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
2,108,662 |
|
- |
|
| Vera Juan |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
2,374,928 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-04-20 |
4 |
S |
$3.63 |
$5,315 |
D/D |
(1,466) |
1,185,055 |
|
13% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-04-20 |
4 |
S |
$3.63 |
$1,265 |
D/D |
(349) |
134,557 |
|
13% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-04-19 |
4 |
S |
$3.71 |
$4,513 |
D/D |
(1,217) |
1,186,521 |
|
17% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-04-19 |
4 |
S |
$3.71 |
$1,291 |
D/D |
(348) |
134,906 |
|
17% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-04-19 |
4 |
S |
$3.71 |
$31,183 |
D/D |
(8,408) |
921,164 |
|
17% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-02-21 |
4 |
AS |
$6.63 |
$33,935 |
D/D |
(5,122) |
929,572 |
|
-47% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
332,500 |
934,964 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
124,006 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
157,500 |
1,187,738 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
61,250 |
135,254 |
|
- |
|
| Miller Edward |
General Counsel |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
87,500 |
235,958 |
|
- |
|
288 Records found
|
|
Page 3 of 12 |
|
|
0.02 (2.93%) 
